Ovarian Cancer Clinical Trial
A Study of DeTIL-0255 in Adults With Advanced Malignancies
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
This study includes a safety run in and a cohort expansion. The safety run in will include patients with any of the indications under study including:
Recurrent or persistent platinum-resistant epithelial ovarian cancer (EOC), including primary peritoneal and fallopian tube carcinoma Recurrent, metastatic, or persistent cervical carcinoma Advanced or recurrent endometrial cancer
Cohort expansion will include patients with advanced malignancies who have received at least two prior systemic therapies in the same indications.
One of the following malignancies: Recurrent or persistent platinum-resistant EOC, recurrent, metastatic or persistent carcinoma of the cervix with progression after treatment with taxane-containing regimen, or advance or recurrent endometrial cancer with disease progression after or during second line or greater therapy
Disease that is metastatic and measurable by RECIST v1.1 criteria
A resectable lesion for TIL generation
At least 2 prior lines of therapy
≥ 18 years and ≤ 70 years of age
Life expectancy of at least 4 months
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Adequate organ and bone marrow function, in the absence of growth factors
Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol
A signed consent form indicating that the subjects understands the purpose and procedures required for the study
Known untreated brain metastases
Uncontrolled intercurrent illness
History of known seizure disorder
Unable to comply with study requirements
Toxicities from previous anticancer therapies that have not resolved to baseline levels or to Grade 1 or less except for alopecia and peripheral neuropathy
Pregnant, breastfeeding, or planning to become pregnant while enrolled on this study or within 6 months after DeTIL infusion
Live vaccine within 28 days of first dose of NMA chemotherapy or planned live vaccination within 6 months following DeTIL infusion
Active known second malignancy with the exception of any of the following: Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or adequately treated follicular or papillary thyroid cancer; or any other cancer from which the patient has been disease-free for ≥ 2 years
Systemic anti-cancer therapy, including investigational agents, or radiotherapy within 4 weeks of tumor resection
Major surgery within 4 weeks before tumor resection, or will not have fully recovered from surgery, or has surgery planned within 8 weeks after infusion
Use of systemic corticosteroids within 15 days (or other immunosuppressive drugs within 30 days) prior to tumor resection
Use of biotin or other supplements containing higher that the daily adequate intake of biotin
Clinically significant, uncontrolled cardiac, class III or IV heart failure, thromboembolic events, cardiovascular disease, or history of myocardial infarction within 6 months of planned start of study drug
History or current evidence of anything that might confound the results of the study
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
New Brunswick New Jersey, 08901, United States
Buffalo New York, 14203, United States
Pittsburgh Pennsylvania, 15212, United States
Pittsburgh Pennsylvania, 15213, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.